Actavis Confirms Favorable Ruling In Generic Pulmicort RESPULES Patent Suit

Mon Apr 1, 2013 5:42pm EDT

* Reuters is not responsible for the content in this press release.

For best results when printing this announcement, please click on the link

PARSIPPANY, N.J.,  April 1, 2013  /PRNewswire/ -- Actavis, Inc. (NYSE: ACT)
today confirmed that the United States District Court for the District of  New
Jersey  has ruled that Actavis' generic version of AstraZeneca's Pulmicort
RESPULES®  (budesonide inhalation suspension) 0.25, 0.5 mg, and 1 mg  vials do
not infringe United States Patent No. 7,524,834  (the '834 Patent) and that
United States Patent No. 6,598,603 (the '603 Patent) is invalid.  Actavis
intends to launch the 0.25 and 0.5 mg products immediately.

Actavis' Abbreviated New Drug Application ("ANDA") for its generic version of
Pulmicort RESPULES®  in the 0.25 and 0.5 mg strengths received final approval
from the U.S. Food and Drug Administration in August 2012.  Actavis' ANDA for
the 1 mg strength is still pending.

Pulmicort RESPULES®  is a maintenance medicine used to control and prevent
asthma symptoms in children ages 12 months to 8 years.  For the 12 months ended 
January 31, 2013, total U.S. brand and generic sales of Pulmicort RESPULES® 
were approximately  $1.2 billion.

Actavis will provide an update of its 2013 forecast on its Q1 2013 earnings
conference call, which it expects to hold on  May 2, 2013.  

About Actavis

Actavis, Inc. (NYSE: ACT) is a global, integrated specialty pharmaceutical
company focused on developing, manufacturing and distributing generic, brand and
biosimilar products.  The Company has global and U.S. headquarters in 
Parsippany, New Jersey, USA, and international headquarters in Zug, Switzerland.

Actavis is the world's third-largest generics prescription drug manufacturer. 
Operating as Actavis Pharma, the Company develops, manufactures and markets
generic, branded generic, legacy brands and Over-the-Counter (OTC) products in
more than 60 countries.  The Company is ranked in the top 3 in 12 global
markets, the top 5 in 16 global markets, and in the top 10 in 33 global markets.
 Actavis Pharma also develops and out-licenses generic pharmaceutical products
outside the U.S. through its Medis third-party business, the world's largest
generic pharmaceutical out-licensing business. Medis has more than 300 customers
globally, and offers a broad portfolio of more than 200 products.   

Actavis Specialty Brands is the Company's global branded specialty
pharmaceutical business, which develops and markets a portfolio of approximately
40 products principally in  the United States  and  Canada  that are focused in
the Urology and Women's Health therapeutic categories.  Actavis Specialty Brands
is committed to developing and marketing biosimilars products in Women's Health,
Oncology and other therapeutic categories, and currently has a portfolio of 5
biosimilar products in development.  

Actavis Global Operations has more than 30 manufacturing and distribution
facilities around the world, with a capacity of approximately 44 billion units
annually.  Actavis Global Operations also includes Anda, Inc., the
fourth-largest U.S. generic pharmaceutical product distributor in  the United

For press release and other company information, visit Actavis' Web site at

Forward-Looking Statement  

Statements contained in this press release that refer to non-historical facts
are forward-looking statements that reflect Actavis' current perspective of
existing information as of the date of this release. It is important to note
that Actavis' goals and expectations are not predictions of actual performance.
Actual results may differ materially from Actavis' current expectations
depending upon a number of factors affecting Actavis' business. These factors
include, among others, the inherent uncertainty associated with financial
projections; the difficulty of predicting the timing or outcome of product
development efforts and FDA approvals or actions, if any; the difficulty of
predicting the timing or outcome of the pending patent litigation, including
potential appeals, and risks that an adverse outcome in such litigation and
appeals could render Actavis liable for substantial damages; the impact of
competitive products and pricing; the timing and success of product launches;
difficulties or delays in manufacturing; the availability and pricing of third
party sourced products and materials; successful compliance with FDA and other
governmental regulations applicable to Actavis and its third party
manufacturers' facilities, products and/or businesses; and such other risks and
uncertainties detailed in Actavis' periodic public filings with the Securities
and Exchange Commission, including but not limited to Actavis' annual report on
Form 10-K for the year ended  December 31,2012. Except as expressly required by
law, Actavis disclaims any intent or obligation to update these forward-looking

Pulmicort RESPULES®  is a registered trademark of the AstraZeneca group of

 CONTACTS:  Investors:        
            Lisa DeFrancesco  
            (862) 261-7152    
            Charlie Mayr      
            (862) 261-8030    


SOURCE  Actavis, Inc.

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.